Navigation Links
Exposure to insecticide may play role in obesity epidemic among some women
Date:3/19/2009

hers who were studied are part of a larger cohort of Michigan fish eaters along Lake Michigan who were recruited in the early 1970s. In 2000, Osuch and research partners approached the cohort and began to identify daughters aged 20 to 50 years old.

"These findings not only apply to the offspring of women in our cohort but to any woman who has been exposed to high levels of DDE when she was growing in her mother's womb," Osuch said. "Mothers with the highest DDE levels are women who have consumed a lot of fish or high-fat meats."

Current recommendations for eating fish call for limiting it to two meals per week; including tuna fish sandwiches. The study also looked at the effects of a second pollutant, PCBs, but found no correlation with weight and body mass index.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Page: 1 2

Related biology news :

1. How increased UV exposure impacts plants
2. Swimmers at public beaches show increased risk of exposure to contagious staph bacteria
3. Novel technique changes lymph node biopsy, reduces radiation exposure
4. Novel technique changes lymph node biopsy, reduces radiaiton exposure
5. Benefits of breastfeeding outweigh risk of infant exposure to environmental chemicals in breastmilk
6. Study reveals effects of unconscious exposure to advertisements
7. Household exposure to toxic chemicals lurks unrecognized, researchers find
8. Major source of radon exposure overlooked at former Ohio uranium-processing plant
9. Birth control has long-term effect on hormone exposure
10. Study: Bird diversity lessens human exposure to West Nile Virus
11. Expert urges FDA to take action to reduce BPA exposure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Exposure to insecticide may play role in obesity epidemic among some women
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... of Virginia Health System have shown for the first ... in muscle cells can reverse myotonic dystrophy, the most ... About 40,000 people in the United States have myotonic ... progressive wasting of the muscles, irregular heartbeat, cataracts and ...
... device designed to "zap" away migraine pain before it starts ... people who suffer from the debilitating disease. , Results ... be effective in eliminating the headache when administered during the ... the Ohio State University Medical Center neurology investigators, was presented ...
... of the newest and most powerful tools of biomedical ... researchers have scored a dramatic success in the battle ... to use what are known as "small interfering RNAs" ... implanted in laboratory mice. Small interfering RNAs (siRNAs), first ...
Cached Biology News:Toxic molecule may cause most common type of muscular dystrophy 2Device effective in zapping the pain out of migraines 2RNA interference stops colon cancer spread in mice 2
(Date:3/30/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier provider ... culture shaping worldwide, today  announced that John ... Healthcare and Life Sciences practice. As Global Practice ... a team of more than 80 partners, principals and associates ... Asia serving clients in the biopharmaceutical, medical ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3